Appetite quiets down
Most patients notice cravings, snacking and food noise drop within days of starting.
Ozempic® is the brand name for semaglutide, a GLP-1 receptor agonist originally approved for type-2 diabetes and now widely prescribed for weight management. It reduces hunger, slows gastric emptying, and improves insulin response.
Six-month trajectories from clinical data of the underlying molecules. GLP-1 produces continued, compounding loss; lifestyle changes alone tend to plateau and rebound.
Every body is different. These are the patterns we see most often across thousands of women on this protocol.
Most patients notice cravings, snacking and food noise drop within days of starting.
Body-weight reduction starts showing up on the scale and in how clothes fit.
Steady weekly loss with provider-guided dose titration. Mood and energy stabilize.
Average 15–20% body weight reduction in clinical data, with maintenance protocols built in.
Quick health questionnaire — about 5 minutes. We use it to match you to the right medication and dose.
A US-licensed clinician reviews your full profile and either prescribes or comes back with a question.
Your medication arrives free of charge with everything you need to start. Provider support is included.
The active molecule is the same. Ozempic® is FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared by licensed compounding pharmacies — typically at a much lower cost.
Sometimes — especially if you have type-2 diabetes. Coverage for weight loss alone is harder. We check coverage during your assessment.